NEW YORK (GenomeWeb News) – Rosetta Genomics disclosed after the close of the market on Thursday that it has been told by Nasdaq that it falls short of a listing requirement and could face delisting.
In a document filed with the US Securities Exchange Commission, the Israeli firm said it received a letter from Nasdaq on Dec. 6 saying its stockholders' equity had fallen below the minimum $2.5 million required to remain listed on the Nasdaq Capital market.